LifeCell, India’s first and largest stem cell bank in the country, a pioneer in stem cell research, has launched to develop large-scale manufacturing of mesenchymal stem cells (MSCs).
Mesenchymal stem cells are one type of master stem cells that can possibly form bone, cartilage, muscle and adipose tissues, in this way making them capable for being utilized as a part of the several therapeutic areas.
Significantly these MSC’s can be made available off-the-shelf for immediate treatment as they needn’t bother with donor-recipient matching.
The capability of these MSCs of medical conditions are being checked in 50+ clinical trials around the world, with several companies like TiGenix, Mesoblast, and etc., are also receiving market approvals in many countries such as Europe, Canada, Japan, and Australia.
Recently in India, to Stempeutics the DCGI provided a limited approval to market their MSC product for the treatment of critical limb ischemia.
Two novel highlights of the program started by LifeCell are that it would use infant umbilical rope inferred MSC’s rather than adult bone marrow-derived MSC’s, as these umbilical lines derived MSC’s have a better survival rate, replicate faster and for a longer time before reaching senescence, mostly because of the way that umbilical cord stem cells (UCSCs) are more primitive or energetic in nature than adult-derived bone marrow stem cell (BMSC).
Additionally, LifeCell would employ large scale and automated 3D Bioreactors rather than traditional tissue flasks, resulting in faster growth and lowering down the cost altogether.
At the appropriate time, LifeCell would start clinical trials after obtaining necessary regulatory approvals, and furthermore set up a new manufacturing facility to help market needs.
Talking about the initiative, Mayur Abhaya, MD, LifeCell stated, “This initiative would allow individuals to have an access of high quality of MSCs and we are extremely glad to make the first move in the industry by making it reasonable by providing a high quality of stem cells for treatment. We are sure we would have the capacity to make this product available in the country in the coming years which would meet the unmet need for better results. For stem cell banking clients, it would offer many benefits as families would now be able to get immediate, off-the-shelf access of these stem cells instead of waiting up to 12 weeks for clinical expansion of their baby’s stem cells.”
In the light of this development, LifeCell will also make improvements to its stem cell banking program, whereby rather than private banking of umbilical cord tissue, it would on the other hand offer donor-derived umbilical cord tissue MSC’s.
LifeCell, set up in 2004, is India’s driving provider of preventive health care services for family health, such as stem cell banking and diagnostic, with facilities at Chennai and Gurgaon with a network spanning more than 200 cities in India and abroad.
BabyCord, LifeCell’s umbilical cord stem cell preservation services, is world’s second biggest with more than 50,000 parents preserving their baby’s stem cells with it every year and around 3,00,000 lakh parents currently having trusted LifeCell.